Live price temporarily unavailable.
Bicycle Therapeutics (BCYC) is a Health Care company. Latest news and coverage below.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $2.06M | $7.14M | $13.8M | $10.4M | $11.7M | $14.5M | $27.0M | $35.3M | $72.6M |
| Growth (year over year) | — | +246.4% | +93.4% | −24.7% | +12.6% | +23.6% | +86.5% | +30.8% | +105.8% |
| Operating income | −$16.2M | −$21.7M | −$26.3M | −$52.0M | −$65.6M | −$116.7M | −$189.9M | −$209.9M | −$247.1M |
| Operating margin | −787.0% | −304.7% | −190.6% | −500.1% | −561.0% | −806.6% | −704.1% | −595.0% | −340.4% |
| Net income | −$16.3M | −$21.8M | −$30.6M | −$51.0M | −$66.8M | −$112.7M | −$180.7M | −$169.0M | −$219.0M |
| Net margin | −789.3% | −306.1% | −221.8% | −491.0% | −571.2% | −779.3% | −669.7% | −479.2% | −301.7% |
| EPS (diluted) | −$48.81 | −$49.78 | −$2.77 | −$2.66 | −$2.67 | −$3.80 | −$5.08 | −$2.90 | −$3.16 |
| Balance sheet | |||||||||
| Cash and equivalents | $67.7M | $0 | $0 | $0 | $438.7M | $339.2M | $526.4M | $879.5M | $628.1M |
| Total assets | — | $81.6M | $110.2M | $161.2M | $479.8M | $410.6M | $595.3M | $956.9M | $717.6M |
| Total liabilities | — | $29.3M | $17.0M | $65.7M | $133.5M | $139.8M | $224.4M | $163.8M | $107.6M |
| Long-term debt | — | — | — | $14.5M | $29.9M | $30.3M | $30.7M | — | — |
| Shareholders' equity | −$47.2M | −$69.8M | $93.2M | $95.5M | $346.3M | $270.8M | $370.9M | $793.1M | $610.0M |
| Cash flow | |||||||||
| Operating cash flow | −$1.42M | −$26.1M | −$28.6M | −$17.8M | −$14.8M | −$86.1M | −$60.6M | −$164.7M | −$249.7M |
| Capital expenditure | $1.11M | $1.19M | $1.55M | $1.20M | $2.03M | $19.0M | $2.93M | $1.24M | $2.35M |
| Free cash flow | −$2.53M | −$27.3M | −$30.2M | −$19.0M | −$16.8M | −$105.1M | −$63.6M | −$166.0M | −$252.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.68M | $3.71M | $9.98M | $2.92M | $11.7M | — | $887.0K | $629.0K |
| Growth (year over year) | −50.0% | −30.4% | −48.9% | −68.8% | +338.5% | — | −91.1% | −78.5% |
| Operating income | −$63.8M | −$67.7M | −$70.2M | −$86.6M | −$65.6M | — | −$65.5M | −$54.6M |
| Operating margin | −2385.9% | −1824.8% | −703.7% | −2965.8% | −558.6% | — | −7382.4% | −8673.9% |
| Net income | −$50.8M | −$51.9M | −$60.8M | −$79.0M | −$59.1M | — | −$60.8M | −$50.3M |
| Net margin | −1898.4% | −1398.4% | −608.9% | −2703.8% | −503.7% | — | −6857.4% | −8002.1% |
| EPS (diluted) | −$0.74 | −$0.77 | −$0.88 | −$1.14 | −$0.85 | — | −$0.87 | −$0.72 |
| Balance sheet | ||||||||
| Cash and equivalents | $890.9M | $879.5M | $793.0M | $721.5M | $648.3M | $628.1M | $559.5M | $510.1M |
| Total assets | $996.7M | $956.9M | $883.9M | $832.2M | $764.0M | $717.6M | $652.4M | $606.6M |
| Total liabilities | $165.7M | $163.8M | $143.6M | $163.3M | $145.5M | $107.6M | $98.1M | $96.3M |
| Shareholders' equity | $831.0M | $793.1M | $740.3M | $668.9M | $618.5M | $610.0M | $554.3M | $510.3M |
| Cash flow | ||||||||
| Operating cash flow | −$39.8M | −$9.40M | −$86.4M | −$72.8M | −$71.2M | — | −$65.9M | −$49.6M |
| Capital expenditure | $435.0K | $368.0K | $604.0K | $498.0K | $674.0K | — | $713.0K | $265.0K |
| Free cash flow | −$40.3M | −$9.76M | −$87.0M | −$73.3M | −$71.8M | — | −$66.6M | −$49.9M |
From Bicycle Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Bicycle Therapeutics in our feed yet.